AbbVie (NYSE:ABBV) Trading Down 2% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV) was down 2% during mid-day trading on Thursday . The stock traded as low as $223.02 and last traded at $224.1250. Approximately 5,294,746 shares changed hands during trading, a decline of 29% from the average daily volume of 7,508,581 shares. The stock had previously closed at $228.72.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $1.73 per share, reinforcing AbbVie’s income profile (Dividend King status) and supporting long-term investor appeal. AbbVie Declares Quarterly Dividend
• Positive Sentiment: Coverage and retail-focussed pieces highlight AbbVie as a durable dividend stock to hold for multi-year income, which can underpin demand from yield-focused investors. 2 Dividend Stocks to Hold for the Next 5 Years
• Positive Sentiment: Pipeline progress is getting attention — recent filings (e.g., Rinvoq for vitiligo) and broader post-Humira portfolio developments prompt some investors to re-evaluate AbbVie’s growth outlook beyond legacy Humira sales. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Positive Sentiment: AbbVie reported completion of a VOLITE skin-quality trial milestone — clinical progress in dermatology could support commercial upside for portfolio assets if follow-up data read out positively. AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
• Neutral Sentiment: Analyst and media pieces (Zacks, Yahoo, others) are re-assessing AbbVie after strong earnings and new filings; this keeps the stock in focus but doesn’t move consensus decisively — coverage is mixed between positive read-throughs and valuation scrutiny. Top Analyst Reports for AbbVie, RTX & IBM
• Negative Sentiment: Evercore lowered its price target slightly (from $232 to $228) and flagged that while Tremfya is gaining share, future earnings growth may be limited — that analyst caution helps explain downward pressure on the stock today. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a report on Tuesday, November 4th. Evercore decreased their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Finally, Piper Sandler increased their price objective on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $251.56.

AbbVie Trading Down 2.0%

The firm has a 50-day simple moving average of $224.01 and a two-hundred day simple moving average of $221.68. The company has a market capitalization of $396.12 billion, a price-to-earnings ratio of 94.97, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the company earned $2.16 EPS. The firm’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

Institutional Investors Weigh In On AbbVie

Institutional investors and hedge funds have recently modified their holdings of the business. Diversified Trust Co raised its holdings in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after acquiring an additional 10,891 shares during the period. Permanent Capital Management LP acquired a new stake in shares of AbbVie in the third quarter valued at about $720,000. Railway Pension Investments Ltd increased its stake in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the period. World Investment Advisors lifted its position in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after purchasing an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co grew its holdings in AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after buying an additional 15,502 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.